Annotation of Pharmaceuticals and Medical Devices Agency, Japan (PMDA) label information
for dapsone
and G6PD
Summary
The PMDA package insert for dapsone (PROTOGEN) states that hemolysis may occur in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Annotation
Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.
Excerpt from the package insert for dapsone (PROTOGEN):
Patients with a glucose-6-phosphate dehydrogenase deficiency (hemolysis may occur).
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the dapsone package insert (in Japanese).
*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.